Cerevel Therapeutics Inc. has identified compounds acting as muscarinic M4 receptor agonists reported be useful for the treatment of pain, sleep disorders, schizophrenia, substance abuse and ...
Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...
Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 ...
Researchers from China Pharmaceutical University and Jiangsu Nhwa Pharmaceutical Co. Ltd. have synthesized azetidine-containing compounds acting as muscarinic M4 receptor positive allosteric ...
Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...
Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...
In a previous article, I made the case that little has changed within the antipsychotic drug landscape over the past 70 years since the only effective medications for the treatment of schizophrenia ...
The US Food and Drug Administration (FDA) is due to issue a decision by September 26 on the approval of KarXT, a potential first-in-class antipsychotic. If approved, it would be the first drug with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback